Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) is a healthcare company (drug manufacturers - general) based in the United States. The share price is $60.90, down 3.23% on the day, which values the company at $124.48B. Price as of 17 Nov 2026, 17:22 UTC, from Yahoo Finance.
Key facts
- Share price
- $60.90−3.23% today
- Market value
- $124.48B
- P/E ratio
- 13.5×last 12 months
- Forward P/E
- 9.1×
- Dividend yield
- 4.00%
- Funk Score
- 57/100
- Against its own history
- Below its usual priceusual price $81.54
- 200-week average
- $55.3010% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Bristol-Myers Squibb Company in more detail
BMY trades at 13.5× its last twelve months' earnings, 9.1× next year's expected earnings, 2.5× sales. Measured against its own history, the price is 25% below what its usual multiples would imply ($81.54) — below its usual price. It sits 10% above its 200-week average of $55.30.
Over the last five fiscal years Bristol-Myers Squibb Company has compounded revenue 2.5% a year, free cash flow -0.7% a year. Its Funk Score is 57 out of 100 (financial strength 5.0, profitability 9.0, growth 2.3, value 6.7, each out of 10).
In its favour: Strong Piotroski score; High return on invested capital.
15 of the superinvestors tracked here hold BMY, including Richard Pzena (2.6% of the portfolio), Thomas Kahn (1.6% of the portfolio), Josef Lakonishok (1.1% of the portfolio).
Superinvestors holding BMY
15 of the investors tracked here report a position in their latest 13F filing.
- Richard Pzena Pzena Investment Management2.61% of portfolio · $888.9M · trimmed · Q3 2026
- Thomas Kahn Kahn Brothers1.61% of portfolio · $9.7M · trimmed · Q3 2026
- Josef Lakonishok LSV Asset Management1.10% of portfolio · $592.6M · trimmed · Q3 2026
- Primecap team Primecap Management0.98% of portfolio · $1.6B · added · Q3 2026
- Bill Miller (founder) Miller Value Partners0.94% of portfolio · $4.3M · Q3 2026
- Cliff Asness AQR Capital Management0.55% of portfolio · $1.6B · trimmed · Q2 2026
- Mark Boyar Boyar Asset Management0.47% of portfolio · $754.3K · trimmed · Q3 2026
- John Rogers Ariel Investments0.43% of portfolio · $41.3M · trimmed · Q3 2026
- John Overdeck and David Siegel (founders) Two Sigma Investments0.36% of portfolio · $491.7M · trimmed · Q3 2026
- Tweedy, Browne team Tweedy, Browne Company0.22% of portfolio · $2.7M · added · Q3 2026
- Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)0.06% of portfolio · $28.9M · added · Q3 2026
- Murray Stahl Horizon Kinetics0.03% of portfolio · $2.7M · trimmed · Q3 2026
- Mairs & Power team Mairs & Power0.01% of portfolio · $1.5M · Q3 2026
- Rajiv Jain GQG Partners0.01% of portfolio · $6M · trimmed · Q3 2026
- Sarah Ketterer Causeway Capital Management0.00% of portfolio · $229.2K · new · Q3 2026
Health Care companies of similar size
- PfizerPFE
- DanaherDHR
- Intuitive SurgicalISRG
- Vertex PharmaceuticalsVRTX
- MedtronicMDT
- StrykerSYK
- McKessonMCK
- SanofiSNY
- ModernaMRNA
- CVS HealthCVS
- HCA HealthcareHCA
- GSKGSK
Side by side:BMY vs MDT (Bristol-Myers Squibb Company vs Medtronic)BMY vs SYK (Bristol-Myers Squibb Company vs Stryker)BMY vs MCK (Bristol-Myers Squibb Company vs McKesson)BMY vs VRTX (Bristol-Myers Squibb Company vs Vertex Pharmaceuticals)BMY vs SNY (Bristol-Myers Squibb Company vs Sanofi)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Bristol-Myers Squibb Company (BMY): questions and answers
What is BMY's P/E ratio?
Bristol-Myers Squibb Company trades at 13.5× its last twelve months' earnings and 9.1× next year's expected earnings. At its fiscal year-ends over the past 17 years the P/E ranged from 4.7× to 100.5×, with a median of 22.1×.
What is BMY's PEG ratio?
Bristol-Myers Squibb Company's PEG ratio is 17.39 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company is valued at $124.48B at a share price of $60.90.
Is BMY overvalued or undervalued?
Against its own history, BMY is below its usual price: the price is 25% below the $81.54 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is BMY above its 200-week moving average?
Yes. BMY is 10.1% above its 200-week average of $55.30. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Bristol-Myers Squibb Company growing?
Over the last five fiscal years Bristol-Myers Squibb Company's revenue grew 2.5% a year; over ten years revenue grew 11.3% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Bristol-Myers Squibb Company (BMY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BMY
Underlying data: Yahoo Finance; company filings with the SEC.